alemtuzumab

Ligand id: 6770

Name: alemtuzumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: alemtuzumab

References
1. Crowe JS, Hall VS, Smith MA, Cooper HJ, Tite JP. (1992)
Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material.
Clin. Exp. Immunol.87 (1): 105-10. [PMID:1339322]
2. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D. (1998)
Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
Leuk. Res.22 (2): 185-91. [PMID:9593475]
3. Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA et al.. (2016)
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Neurology,  [Epub ahead of print]. [PMID:27733571]
4. Shitara K, Niwa R, Natsume A. (2011)
Recombinant antibody composition.
Patent number: US7923538. Assignee: Kyowa Hakko Kirin Co., Ltd. Priority date: 22/07/2005. Publication date: 12/04/2011.
5. Shitara K, Niwa R, Natsume A. (2011)
Recombinant antibody composition.
Patent number: US7923538 B2. Assignee: Kyowa Hakko Kirin Co., Ltd. Priority date: 22/07/2005. Publication date: 12/04/2011.